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A
lternating between positions in 
Europe and the U.S., Hidde 
Ploegh has studied immunology 
from all sides of the equation and on both 
sides of the Atlantic. As a bicontinental 
graduate student, Ploegh fi  rst entered the 
competitive world of immunology by 
cloning a cDNA for a human major 
histocompatibility complex (MHC) mole-
cule (1)—one of the glycoproteins that 
present antigens on the cell surface. <ID>JCB1793pi1 .eps</ID>
Since then, his focus on MHC has not 
wavered, although it has broadened. In ad-
dition to MHC syn-
thesis and traffi  ck-
ing (2), Ploegh has 
also studied patho-
gens that hide by 
impairing MHCs 
(3) and the cellular 
protein degradation 
pathways that pro-
vide MHCs with 
their antigens, in-
cluding the ubiqui-
tin–proteasome 
system. He has developed new chemical 
tools to study proteasome activity and 
the roles of lysosomal and ubiquitin-
specifi  c proteases (4).
In 2005, Ploegh joined the Whitehead 
Institute, whose members hold faculty 
appointments at MIT. He recently discussed 
with us the career path that led him there, 
what he sees as some of the drawbacks of 
doing research at a medical school, and 
his zest for fi  shing and science.
POSTDOC IMMUNITY
What ﬁ  rst piqued your interest in 
immunology?
As an undergrad, I read an interview in 
the Dutch equivalent of Ladies’ Home 
Journal with one of the leading Dutch 
immunologists, Jon van Rood. I wrote 
him a letter asking whether I could work 
in his lab, but I never got an answer.
At the time, I was working for my 
undergraduate advisor, whose interests 
were in bacterial cell walls and membrane 
structure. He had some fi  nancial resources 
to allow his graduate students to go abroad 
to learn techniques and bring these back 
to his lab.
Since his two graduate students weren’t 
particularly interested in this opportunity, 
he turned to me. He wrote letters explain-
ing the purpose to a number of investiga-
tors, mostly in the U.S. One of the few 
who wrote back in the affi  rmative  was 
Jack Strominger, who was working at 
Harvard on bacterial cell wall synthesis.
To my surprise—this was before Internet 
days—when I arrived, it turned out that half 
the Strominger lab was working on the bio-
chemistry of transplantation antigens. Then 
and there, it became clear to me that that 
would be a great topic to return to. My six-
month visit concluded with an agreement 
that I’d return as a graduate student and 
work on transplantation antigens.
For that, I got some fi  nancial support 
from the Dutch government. And who 
should be sitting on the selection commit-
tee but van Rood. As luck would have it, 
he even became my formal thesis advisor. 
I did the practical work for my graduate 
studies in Jack Strominger’s lab, but de-
fended my thesis in the Netherlands.
In 1980, I left the Strominger lab and 
took my fi  rst independent position.
You never did a postdoc?
Correct. My thesis project consisted of 
cloning cDNA for a major histocompatibili-
ty antigen. I think that work attracted the 
attention of Klaus Rajewsky, who was the 
head of immunology at the University of 
Cologne in Germany. He wondered wheth-
er I would be interested in taking a junior 
group leader position at that institute.
What was it like, running a lab directly 
after your Ph.D.?
I think the fi  rst students you work with 
suffer the consequences. You have no ex-
perience leading a lab, you make all the 
mistakes that you can make. Objectively 
speaking, not much was produced, but I 
do think I learned how not to run a lab.
RAMBLING MAN
But you didn’t stay there long. In fact, 
you rarely seem to stay at any one place 
very long.
No, my next slot was at the Netherlands 
Cancer Institute. I was invited to join in 
1984 by Piet Borst. He had just become 
the institute’s director and was interested 
in infusing some fresh blood. I led a group 
in the cell biology and biochemistry of 
antigen presentation.
In ’92 I was approached by Susumu 
Tonegawa. He asked whether I might be 
interested in moving to MIT. That was an 
opportunity that I couldn’t turn down.
I stayed there until ’97, when Harvard 
Medical School wanted to know if I was 
interested in moving there. I had gotten to 
know several colleagues there when we 
served as editors for Immunity. I also had 
a very strong interest in the didactic mis-
sions of school, and they were looking for 
a person to take charge of the graduate 
program in immunology.
That lasted until 2005, and then I was 
recruited to Whitehead.
How was returning to the States in the 
early ‘90s?
I think the scientifi  c climate in the U.S. to 
this day is more vibrant and lively than 
most places in Europe. I’m not dinging 
Europe in the least, I enjoyed every moment 
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From the moment he ﬁ  nished his Ph.D., Hidde Ploegh has been a wanted man. 
Invited to join one institution after another, he always packed with him his 
keen interests in the immune system.
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I lived in Amsterdam, but I think the in-
tensity with which people pursue their 
science is just on a different level. 15 
years ago, that was certainly true, al-
though the difference seems to be less 
pronounced today. The resources available, 
the intellectual fi   repower, the Boston 
academic climate with MIT, Harvard, 
and Harvard Medical School, it’s just 
beyond compare.
You seem to have an afﬁ  nity for the 
Boston area.
Yes, I do. As it happens, I like to fi  sh. I 
would say Boston is the saltwater fl  y-fi  sh-
ing capital of the world. I co-own a little 
fi  shing  boat,  The  Rampage, with my 
Harvard colleague, Fred Alt. We go out 
for striped bass, bluefi  sh,  bluefi  n  tuna 
with varying degrees of success.
What made you decide to leave Harvard 
Medical School for Whitehead/MIT?
<ID>JCB1793pi2 .eps</ID>There are several issues associated with 
working at a medical school. Many have 
hospitals affi  liated with them, and the eco-
nomics and logistics of that imposes a 
certain organizational structure. The primary 
mission of a medical school is naturally to 
train doctors. To give you an example, I 
had to talk to the head of our public affairs 
department two years in a row before the 
annual Dean’s report began highlighting 
the various graduate programs. It would 
showcase the medical students and the 
M.D./Ph.D. students, but the graduate pro-
grams seemed like an afterthought.
I felt that the Whitehead/MIT environ-
ment was more curiosity driven and less 
concerned with medically relevant re-
search. There’s nothing wrong with that 
in principle, but for me, it’s like the differ-
ence between Italian and French cuisine. 
They’re both outstanding if properly pre-
pared, but some people prefer French, 
others, Italian. It has nothing to do with 
quality per se, just a difference in style.
My recent research interests are also 
better aligned with what MIT is really 
good at: chemistry, materials science, engi-
neering, and so forth. Lately, I’ve become 
more and more interested in engineering-
based approaches to biological questions.
If you enter the building where the 
mechanical engineers are, and you see the 
posters on the wall, you’ll see so much 
ingenuity, such diversity of approaches. 
I’m always struck by the eagerness of 
faculty in other departments to get in-
volved, get their hands dirty, think about 
possibilities for joint projects. There’s a 
growing awareness that interdisciplinary 
interactions—where one can combine, 
say, physics with biology—can produce 
so much more. Compare that with your 
typical medical school, where everything 
of necessity is focused on either basic 
biology or translational stuff.
WHERE THE PASSION LIES
In all your locales, one constant has 
been your interest in MHCs.
Yes, that is perhaps unusual. Most graduate 
students change tack when they do a post-
doc and maybe again once they become 
independent, but I haven’t really felt the 
need. The work I started as a graduate 
student still continues today, in a different 
incarnation, of course. Ever since I start-
ed working on these MHC products, I’ve 
been interested in how they’re put to-
gether from their building blocks, how 
they travel from the site of synthesis to 
their destination.
Another unusual aspect of your career 
is that you were always invited to your 
next position.
True, I’ve never even applied for a job. I 
have been in a very privileged position, 
but I think a big part of it is just being 
enthusiastic about what you do.
What I’ve learned is that the single 
most important thing is passion. You also 
have to take pleasure in the details: the 
duplicates of a calibration curve falling 
right on top of one another or bands on a 
gel coming out razor sharp, in addition to 
real discoveries. To this very day, there’s 
almost nothing I’d rather do than look at 
autorads. Get a life, right?
And why do you have such a passion 
for research?
It’s the most exciting profession I could 
imagine. It’s like a stem cell, continuous-
ly self-renewing. The next day is almost 
always as exciting as the preceding one.
It’s hard to imagine fi  nding a work-
ing environment that is so dependent on 
the social aspects. Many students are 
under the mistaken impression that be-
ing a scientist means being somewhat of 
a recluse. Some future medical students 
think that because they see patients, they 
get a richer experience of interpersonal 
interactions. Sure, if you enjoy dealing 
with HMOs rather than working with 
your peers, debating puzzles, and think-
ing creatively… But I know which side 
my bread is buttered on.
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Ploegh and ﬁ  shing partners Tom Look (middle) 
and Fred Alt (right) enjoy fishing for ideas 
and the occasional blueﬁ  n tuna.